Cadent Therapeutics Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
25
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$770M
Cadent Therapeutics General Information
Description
Operator of a precision neuroscience company intended to develop drugs focused on psychiatric diseases. The company's firm develops small molecule therapeutics targeting the NMDA (N-Methyl-D-Aspartate) receptor to treat spinocerebellar ataxia, essential tremor, neuropsychiatric disorders, schizophrenia, and other cognitive and neuropsychiatric disorders, thereby enabling hospitals to restore brain rhythms and improve outcomes in patients living with movement, mood, and cognitive disorders.
Contact Information
Website
www.cadenttx.comCorporate Office
- 60 Hamilton Street
- Cambridge, MA 02139
- United States
Corporate Office
- 60 Hamilton Street
- Cambridge, MA 02139
- United States
Cadent Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 31-Mar-2021 | $770M | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series B) | 29-Apr-2020 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series A1) | 03-Mar-2017 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series A) | 21-Jun-2013 | Completed | Product Development | |||
| 2. Buyout/LBO | $700K | Completed | Startup | |||
| 1. Seed Round | 14-Nov-2011 | $700K | $700K | Completed | Startup |
Cadent Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 31,790,600 | $0.001000 | 6% | $0.51 | $0.51 | 1x | $0.51 | 24.93% |
Cadent Therapeutics Comparisons
Industry
Financing
Details
Cadent Therapeutics Competitors (38)
One of Cadent Therapeutics’s 38 competitors is Voyager Therapeutics, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| CervoMed | Formerly VC-backed | Boston, MA | ||||
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA |
Cadent Therapeutics Patents
Cadent Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022204337-A1 | Novel cyclopenta[c]pyrrol negative allosteric modulators of nr2b | Inactive | 26-Mar-2021 | ||
| WO-2022204336-A1 | Novel cyclopental[c]pyrrol negative allosteric modulators of nr2b | Inactive | 26-Mar-2021 | ||
| WO-2020086456-A1 | Crystalline forms of potassium channel modulators | Inactive | 22-Oct-2018 | ||
| WO-2020086136-A2 | Heteroaromatic nmda receptor modulators and uses thereof | Inactive | 03-Aug-2018 | ||
| WO-2020086136-A3 | Heteroaromatic nmda receptor modulators and uses thereof | Inactive | 03-Aug-2018 | C07D487/04 |
Cadent Therapeutics Signals
Cadent Therapeutics Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Access Industries | PE/Buyout | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| Clal Biotechnology Industries | Venture Capital | Minority | ||
| Cowen Healthcare Investments | Venture Capital | Minority | ||
| Qiming Venture Partners USA | Venture Capital | Minority |
Cadent Therapeutics Acquisitions (1)
Cadent Therapeutics’s most recent deal was a Merger/Acquisition with Ataxion. The deal was made on 06-Mar-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ataxion | 06-Mar-2017 | Merger/Acquisition | Drug Discovery |
Cadent Therapeutics FAQs
-
When was Cadent Therapeutics founded?
Cadent Therapeutics was founded in 2010.
-
Where is Cadent Therapeutics headquartered?
Cadent Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Cadent Therapeutics?
Cadent Therapeutics has 25 total employees.
-
What industry is Cadent Therapeutics in?
Cadent Therapeutics’s primary industry is Drug Discovery.
-
Is Cadent Therapeutics a private or public company?
Cadent Therapeutics is a Private company.
-
What is the current valuation of Cadent Therapeutics?
The current valuation of Cadent Therapeutics is .
-
What is Cadent Therapeutics’s current revenue?
The current revenue for Cadent Therapeutics is .
-
How much funding has Cadent Therapeutics raised over time?
Cadent Therapeutics has raised $68.3M.
-
Who are Cadent Therapeutics’s investors?
Access Industries, Atlas Venture, Clal Biotechnology Industries, Cowen Healthcare Investments, and Qiming Venture Partners USA are 5 of 6 investors who have invested in Cadent Therapeutics.
-
Who are Cadent Therapeutics’s competitors?
Voyager Therapeutics, CervoMed, NeuroNascent, Cognition Therapeutics, and Neurona Therapeutics are some of the 38 competitors of Cadent Therapeutics.
-
When was Cadent Therapeutics acquired?
Cadent Therapeutics was acquired on 31-Mar-2021.
-
Who acquired Cadent Therapeutics?
Cadent Therapeutics was acquired by Novartis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process